Your browser doesn't support javascript.
loading
Short Communication:Outcomes of Dual Versus Triple Antiretroviral Drug Regimens Among Virally Suppressed Adults in the DC Cohort.
Koay, Wei Li Adeline; Xiao, Jiayang; Temprosa, Marinella; Happ, Lindsey P; Monroe, Anne K; Castel, Amanda D; Rakhmanina, Natella Y.
Afiliação
  • Koay WLA; Division of Infectious Diseases, Children's National Hospital, Washington, District of Columbia, USA.
  • Xiao J; Department of Pediatrics, School of Medicine and Health Sciences, The George Washington University, Washington, District of Columbia, USA.
  • Temprosa M; Department of Biostatistics and Bioinformatics and Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA.
  • Happ LP; Department of Biostatistics and Bioinformatics and Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA.
  • Monroe AK; Department of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA.
  • Castel AD; Department of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA.
  • Rakhmanina NY; Department of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA.
AIDS Res Hum Retroviruses ; 38(6): 451-454, 2022 06.
Article em En | MEDLINE | ID: mdl-35352966
ABSTRACT
This study explored virological outcomes of two-drug (2DRs) and three-drug (3DRs) antiretroviral regimens in adults with HIV in the DC Cohort. We analyzed 310 treatment-experienced adults with sustained HIV RNA ≤50 copies/mL at baseline, 53 of whom switched to 2DRs and 257 continued 3DRs. Adults on 2DRs and 3DRs had similar demographics (median age 53.3 years, 76.8% cisgender male, 76.1% Black). Adults on 2DRs had more participants with ≥2 comorbidities (62.3% vs. 42.8%, p = .019), had a longer time since HIV diagnosis (median years 20.4 vs. 13.2, p = .017), and received the regimen of interest for a shorter duration (median years 1.3 vs. 3.3, p < .001) compared with adults on 3DRs. Adults receiving 2DRs had a higher, although nonsignificant, risk for virological failure (two consecutive HIV RNA ≥50 copies/mL) at 24 months follow-up than adults on 3DRs (6.7% vs. 1.7%, respectively; p = .10). Future analysis of the effectiveness of 2DRs is needed.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Humans / Male / Middle aged Idioma: En Revista: AIDS Res Hum Retroviruses Assunto da revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Humans / Male / Middle aged Idioma: En Revista: AIDS Res Hum Retroviruses Assunto da revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos